|
시장보고서
상품코드
1424963
세계 이식진단 시장 : 시장 규모, 점유율 분석, 기술별, 제공내용별, 이식유형별, 용도별, 최종사용자별 - 산업 수요 예측(-2030년)Transplant Diagnostics Market Size and Share Analysis by Technology, Offering, Transplant Type, Application, End User - Global Industry Demand Forecast to 2030 |
||||||
세계 이식 진단 시장은 2023년에는 46억 8,670만 달러로 평가되었고 2029년 말까지 7.5%의 성장률를 나타낼 전망이며, 2030년에는 77억 1,350만 달러에 이를 것으로 예측됩니다.
이는 장기치환술의 필요성이 증가하고, 장기치환술 전 진단처치의 필요성이 높아지고 있으며, 감염증이 증가하고 있는 것에 기인하고 있습니다.
또한 최종 단계의 장기 부전 환자 수가 증가하는 경향이 있으며, 장기 이식 수술의 발전으로 많은 환자들이 이러한 수술을받을 수 있습니다.
기술별로는 분자 분석이 2023년에 65%의 점유율로 업계를 선도하고 있어 앞으로도 우위를 유지할 것으로 보입니다.
이것은 분자 분석이 수령인과 공여자의 적합성을 검사하기 위해 수술 전 진단 과정에서 널리 사용된다는 사실 때문입니다. 이러한 분석은 비분자 분석과는 대조적으로 수많은 샘플 연구, 순간 분석, 높은 절차적 효능 등 기술적 이점이 있기 때문에 주로 받아들여집니다.
소프트웨어 서비스 부서는 향후 가장 빠르게 성장할 것으로 보입니다. 이는 시장 경쟁에서 각 회사가 제공하는 소프트웨어의 정기적인 업데이트와 충실한 서비스 때문입니다.
또한, 첨단 장비의 확대로 기술 직원에게 장비 취급과 사용법을 가르치는 강습회 수요가 급증하고 있습니다. 이러한 요인이 업계의 진화로 이어지고 있습니다.
이식진단 시장은 2023년에는 진단약 카테고리가 70%의 점유율을 차지하고 있어 앞으로도 이 경향이 계속될 것으로 보입니다. 이것은 질병의 발생이 증가하고 있기 때문입니다.
또한 진단 범주는 이식 전 진단과 이식 후 진단으로 나뉩니다. 또한, 이식 과정에서 이식 전에 모든 상대적인 진단 검사가 이식의 적합성을 확인하기 위해 수행됩니다. 예를 들어 혈액 프로파일링, 조직 적합성 검사, 전염병 검사 등입니다.
2023년에는 북미가 50%로 최대의 점유율을 차지하고 있어 앞으로도 이 경향은 계속될 것으로 보입니다. 이는 최첨단 기술 및 분석 도구의 높은 수용률, 고액의 의료비, 숙련된 전문가의 가용성, 연부 조직 이식, 줄기 세포 치료, 맞춤형 약물의 광범위한 사용과 매우 관련이 있습니다.
게다가 장기 이식의 건수 증가, 이식에 대한 의식 증가, 전염병의 이환율 증가, 만성 질환에 걸리기 쉬운 노인 인구 증가가 이 업계의 원동력이 되고 있습니다.
이 보고서는 세계 이식 진단 시장을 분석하고 시장의 기본 구조, 최신 상황 및 주요 촉진 및 억제요인, 세계 전체 및 지역별 및 주요 국가 시장 규모 동향 전망(금액 기준, 2017-2030년), 기술별·제공내용별·이식유형별·용도별·최종사용자별 상세 동향, 현재 시장 경쟁의 상황, 주요 기업프로파일 등의 정보를 전해드립니다.
목차
제1장 조사 범위
제2장 조사 방법
제3장 주요 요약
제4장 시장 지표
제5장 업계 전망
- 시장 역학
- 동향
- 성장 촉진요인
- 억제요인/과제
- 성장 촉진요인/억제요인의 영향 분석
- 신형 코로나 바이러스 감염(COVID-19)의 영향
- Porter's Five Forces 분석
제6장 시장
- 개요
- 시장 수익 : 기술별(2017-2030년)
- 분자 분석 시장 수익 : 유형별(2017-2030년)
- 비분자 분석 시장 수익: 유형별(2017-2030년)
- 시장 수익 : 제공 내용별(2017-2030년)
- 시장 수익 : 이식유형별(2017-2030년)
- 고형 장기 시장 수익 : 유형별(2017-2030년)
- 시장 수익 : 용도별(2017-2030년)
- 시장 수익 : 최종사용자별(2017-2030년)
- 시장 수익 : 지역별(2017-2030년)
제7장 북미 시장
- 개요
- 시장 수익 : 기술별(2017-2030년)
- 분자 분석 시장 수익 : 유형별(2017-2030년)
- 비분자 분석 시장 수익: 유형별(2017-2030년)
- 시장 수익 : 제공 내용별(2017-2030년)
- 시장 수익 : 이식유형별(2017-2030년)
- 고형 장기 시장 수익 : 유형별(2017-2030년)
- 시장 수익 : 용도별(2017-2030년)
- 시장 수익 : 최종사용자별(2017-2030년)
- 시장 수익 : 국가별(2017-2030년)
제8장 유럽 시장
제9장 아시아태평양 시장
제10장 라틴아메리카 시장
제11장 중동 및 아프리카(MEA) 시장
제12장 미국 시장
- 개요
- 시장 수익 : 기술별(2017-2030년)
- 분자 분석 시장 수익 : 유형별(2017-2030년)
- 비분자 분석 시장 수익: 유형별(2017-2030년)
- 시장 수익 : 제공 내용별(2017-2030년)
- 시장 수익 : 이식유형별(2017-2030년)
- 고형 장기 시장 수익 : 유형별(2017-2030년)
- 시장 수익 : 용도별(2017-2030년)
- 시장 수익 : 최종사용자별(2017-2030년)
제13장 캐나다 시장
제14장 독일 시장
제15장 프랑스 시장
제16장 영국 시장
제17장 이탈리아 시장
제18장 스페인 시장
제19장 일본 시장
제20장 중국 시장
제21장 인도 시장
제22장 호주 시장
제23장 한국 시장
제24장 브라질 시장
제25장 멕시코 시장
제26장 사우디아라비아 시장
제27장 남아프리카 시장
제28장 아랍에미리트(UAE) 시장
제29장 경쟁 구도
- 시장 진출기업과 그 제공 제품/서비스의 일람
- 주요 기업의 경쟁 벤치마킹
- 주요 기업의 제품 벤치마킹
- 최근의 전략 전개 상황
제30장 기업 프로파일
- bioMerieux SA
- Thermo Fisher Scientific Inc.
- Bio-Rad Laboratories Inc.
- Abbott Laboratories
- Hologic Inc.
- F. Hoffmann-La Roche Ltd.
- Laboratory Corporation of America Holdings
- BAG Diagnostics GmbH
- Illumina Inc.
제31장 부록
BJH 24.02.20The transplant diagnostics market was valued at USD 4,686.7 million in 2023, and it will grow at a rate of 7.5% by the end of this decade, to touch USD 7,713.5 million by 2030.
This is attributable to the growing requirement for organ replacement procedures, the growing requirement for diagnostic procedures before organ replacement, and the powering occurrence of communicable diseases.
Also, the number of people with final-stage organ failure is on the rise, and because of the development in organ transplantation procedures, a high number of patients can now access these surgeries.
On the basis of technology, molecular assay led the industry with a share, of 65%, in 2023, and it will continue to dominate in the future as well.
This is due to the fact that molecular assays are extensively used in presurgical diagnostic processes for testing the compatibility of a recipient and donor. These assays are mostly accepted because of their tech benefits as opposed to non-molecular assays, for example the study of numerous samples and instantaneous analysis and high procedural efficacy.
The software & services category will grow the fastest in the future. This is because of the regular updates in software and enhanced services provided by the market players remain in the competition.
Furthermore, the expansion of more progressive instruments has led to a surge in the demand for training sessions to teach technical employees to handle and use an instrument. These factors led to the evolution of the industry.
The diagnostics category dominated the transplant diagnostics market, with a share of 70%, in 2023, and it will continue like this in the future. This is credited to the increasing occurrence of ailments.
Furthermore, the diagnostic category is divided into pre-transplantation and post-transplantation diagnostic. Additionally, for transplant processes, all relative diagnostic tests will be done prior to the transplant to see the compatibility of the transplant for example blood profiling, histocompatibility testing, and communicable disease testing.
North America had the largest share, of 50%, in 2023, and it will continue like this in the future. This has a lot to do with the high acceptance rate of cutting-edge techniques and analytic tools, high healthcare spending, the obtainability of skilled experts, and the extensive use of soft tissue transplants, stem cell therapies, and tailored medications.
Furthermore, the growing count of organ replacements, the increasing consciousness of transplantation, the growing incidence of communicable ailments, and the rising elderly populace susceptible to chronic ailments are powering the industry.
There is an increasing number of organ transplants happening around the world, and this will power the demand for transplant diagnostic solutions. The trend will continue in the years to come as well.
Top Providers of Transplant Diagnostics Are:
bioMerieux S.A.
Thermo Fisher Scientific Inc.
Bio-Rad Laboratories, Inc.
Abbott Laboratories
Hologic Inc.
F. Hoffmann-La Roche Ltd.
Laboratory Corporation of America Holdings
BAG Diagnostics GmbH
Illumina Inc.
Table of Contents
Chapter 1. Research Scope
- 1.1. Research Objectives
- 1.2. Market Definition
- 1.3. Analysis Period
- 1.4. Market Size Breakdown by Segments
- 1.4.1. Market size breakdown, by technology
- 1.4.2. Market size breakdown, by offering
- 1.4.3. Market size breakdown, by transplant type
- 1.4.4. Market size breakdown, by end user
- 1.4.5. Market size breakdown, by application
- 1.4.6. Market size breakdown, by region
- 1.4.7. Market size breakdown, by country
- 1.5. Market Data Reporting Unit
- 1.5.1. Value
- 1.6. Key Stakeholders
Chapter 2. Research Methodology
- 2.1. Secondary Research
- 2.1.1. Paid
- 2.1.2. Unpaid
- 2.1.3. P&S Intelligence database
- 2.2. Primary Research
- 2.3. Market Size Estimation
- 2.4. Data Triangulation
- 2.5. Currency Conversion Rates
- 2.6. Assumptions for the Study
- 2.7. Notes and Caveats
Chapter 3. Executive Summary
Chapter 4. Market Indicators
Chapter 5. Industry Outlook
- 5.1. Market Dynamics
- 5.1.1. Trends
- 5.1.2. Drivers
- 5.1.3. Restraints/challenges
- 5.1.4. Impact analysis of drivers/restraints
- 5.2. Impact of COVID-19
- 5.3. Porter's Five Forces Analysis
- 5.3.1. Bargaining power of buyers
- 5.3.2. Bargaining power of suppliers
- 5.3.3. Threat of new entrants
- 5.3.4. Intensity of rivalry
- 5.3.5. Threat of substitutes
Chapter 6. Global Market
- 6.1. Overview
- 6.2. Market Revenue, by Technology (2017-2030)
- 6.2.1. Molecular assay market revenue, by type (2017-2030)
- 6.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 6.3. Market Revenue, by Offering (2017-2030)
- 6.4. Market Revenue, by Transplant Type (2017-2030)
- 6.4.1. Solid organ market revenue, by type (2017-2030)
- 6.5. Market Revenue, by Application (2017-2030)
- 6.6. Market Revenue, by End User (2017-2030)
- 6.7. Market Revenue, by Region (2017-2030)
Chapter 7. North America Market
- 7.1. Overview
- 7.2. Market Revenue, by Technology (2017-2030)
- 7.2.1. Molecular assay market revenue, by type (2017-2030)
- 7.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 7.3. Market Revenue, by Offering (2017-2030)
- 7.4. Market Revenue, by Transplant Type (2017-2030)
- 7.4.1. Solid organ market revenue, by type (2017-2030)
- 7.5. Market Revenue, by Application (2017-2030)
- 7.6. Market Revenue, by End User (2017-2030)
- 7.7. Market Revenue, by Country (2017-2030)
Chapter 8. Europe Market
- 8.1. Overview
- 8.2. Market Revenue, by Technology (2017-2030)
- 8.2.1. Molecular assay market revenue, by type (2017-2030)
- 8.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 8.3. Market Revenue, by Offering (2017-2030)
- 8.4. Market Revenue, by Transplant Type (2017-2030)
- 8.4.1. Solid organ market revenue, by type (2017-2030)
- 8.5. Market Revenue, by Application (2017-2030)
- 8.6. Market Revenue, by End User (2017-2030)
- 8.7. Market Revenue, by Country (2017-2030)
Chapter 9. APAC Market
- 9.1. Overview
- 9.2. Market Revenue, by Technology (2017-2030)
- 9.2.1. Molecular assay market revenue, by type (2017-2030)
- 9.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 9.3. Market Revenue, by Offering (2017-2030)
- 9.4. Market Revenue, by Transplant Type (2017-2030)
- 9.4.1. Solid organ market revenue, by type (2017-2030)
- 9.5. Market Revenue, by Application (2017-2030)
- 9.6. Market Revenue, by End User (2017-2030)
- 9.7. Market Revenue, by Country (2017-2030)
Chapter 10. LATAM Market
- 10.1. Overview
- 10.2. Market Revenue, by Technology (2017-2030)
- 10.2.1. Molecular assay market revenue, by type (2017-2030)
- 10.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 10.3. Market Revenue, by Offering (2017-2030)
- 10.4. Market Revenue, by Transplant Type (2017-2030)
- 10.4.1. Solid organ market revenue, by type (2017-2030)
- 10.5. Market Revenue, by Application (2017-2030)
- 10.6. Market Revenue, by End User (2017-2030)
- 10.7. Market Revenue, by Country (2017-2030)
Chapter 11. MEA Market
- 11.1. Overview
- 11.2. Market Revenue, by Technology (2017-2030)
- 11.2.1. Molecular assay market revenue, by type (2017-2030)
- 11.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 11.3. Market Revenue, by Offering (2017-2030)
- 11.4. Market Revenue, by Transplant Type (2017-2030)
- 11.4.1. Solid organ market revenue, by type (2017-2030)
- 11.5. Market Revenue, by Application (2017-2030)
- 11.6. Market Revenue, by End User (2017-2030)
- 11.7. Market Revenue, by Country (2017-2030)
Chapter 12. U.S. Market
- 12.1. Overview
- 12.2. Market Revenue, by Technology (2017-2030)
- 12.2.1. Molecular assay market revenue, by type (2017-2030)
- 12.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 12.3. Market Revenue, by Offering (2017-2030)
- 12.4. Market Revenue, by Transplant Type (2017-2030)
- 12.4.1. Solid organ market revenue, by type (2017-2030)
- 12.5. Market Revenue, by Application (2017-2030)
- 12.6. Market Revenue, by End User (2017-2030)
Chapter 13. Canada Market
- 13.1. Overview
- 13.2. Market Revenue, by Technology (2017-2030)
- 13.2.1. Molecular assay market revenue, by type (2017-2030)
- 13.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 13.3. Market Revenue, by Offering (2017-2030)
- 13.4. Market Revenue, by Transplant Type (2017-2030)
- 13.4.1. Solid organ market revenue, by type (2017-2030)
- 13.5. Market Revenue, by Application (2017-2030)
- 13.6. Market Revenue, by End User (2017-2030)
Chapter 14. Germany Market
- 14.1. Overview
- 14.2. Market Revenue, by Technology (2017-2030)
- 14.2.1. Molecular assay market revenue, by type (2017-2030)
- 14.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 14.3. Market Revenue, by Offering (2017-2030)
- 14.4. Market Revenue, by Transplant Type (2017-2030)
- 14.4.1. Solid organ market revenue, by type (2017-2030)
- 14.5. Market Revenue, by Application (2017-2030)
- 14.6. Market Revenue, by End User (2017-2030)
Chapter 15. France Market
- 15.1. Overview
- 15.2. Market Revenue, by Technology (2017-2030)
- 15.2.1. Molecular assay market revenue, by type (2017-2030)
- 15.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 15.3. Market Revenue, by Offering (2017-2030)
- 15.4. Market Revenue, by Transplant Type (2017-2030)
- 15.4.1. Solid organ market revenue, by type (2017-2030)
- 15.5. Market Revenue, by Application (2017-2030)
- 15.6. Market Revenue, by End User (2017-2030)
Chapter 16. U.K. Market
- 16.1. Overview
- 16.2. Market Revenue, by Technology (2017-2030)
- 16.2.1. Molecular assay market revenue, by type (2017-2030)
- 16.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 16.3. Market Revenue, by Offering (2017-2030)
- 16.4. Market Revenue, by Transplant Type (2017-2030)
- 16.4.1. Solid organ market revenue, by type (2017-2030)
- 16.5. Market Revenue, by Application (2017-2030)
- 16.6. Market Revenue, by End User (2017-2030)
Chapter 17. Italy Market
- 17.1. Overview
- 17.2. Market Revenue, by Technology (2017-2030)
- 17.2.1. Molecular assay market revenue, by type (2017-2030)
- 17.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 17.3. Market Revenue, by Offering (2017-2030)
- 17.4. Market Revenue, by Transplant Type (2017-2030)
- 17.4.1. Solid organ market revenue, by type (2017-2030)
- 17.5. Market Revenue, by Application (2017-2030)
- 17.6. Market Revenue, by End User (2017-2030)
Chapter 18. Spain Market
- 18.1. Overview
- 18.2. Market Revenue, by Technology (2017-2030)
- 18.2.1. Molecular assay market revenue, by type (2017-2030)
- 18.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 18.3. Market Revenue, by Offering (2017-2030)
- 18.4. Market Revenue, by Transplant Type (2017-2030)
- 18.4.1. Solid organ market revenue, by type (2017-2030)
- 18.5. Market Revenue, by Application (2017-2030)
- 18.6. Market Revenue, by End User (2017-2030)
Chapter 19. Japan Market
- 19.1. Overview
- 19.2. Market Revenue, by Technology (2017-2030)
- 19.2.1. Molecular assay market revenue, by type (2017-2030)
- 19.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 19.3. Market Revenue, by Offering (2017-2030)
- 19.4. Market Revenue, by Transplant Type (2017-2030)
- 19.4.1. Solid organ market revenue, by type (2017-2030)
- 19.5. Market Revenue, by Application (2017-2030)
- 19.6. Market Revenue, by End User (2017-2030)
Chapter 20. China Market
- 20.1. Overview
- 20.2. Market Revenue, by Technology (2017-2030)
- 20.2.1. Molecular assay market revenue, by type (2017-2030)
- 20.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 20.3. Market Revenue, by Offering (2017-2030)
- 20.4. Market Revenue, by Transplant Type (2017-2030)
- 20.4.1. Solid organ market revenue, by type (2017-2030)
- 20.5. Market Revenue, by Application (2017-2030)
- 20.6. Market Revenue, by End User (2017-2030)
Chapter 21. India Market
- 21.1. Overview
- 21.2. Market Revenue, by Technology (2017-2030)
- 21.2.1. Molecular assay market revenue, by type (2017-2030)
- 21.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 21.3. Market Revenue, by Offering (2017-2030)
- 21.4. Market Revenue, by Transplant Type (2017-2030)
- 21.4.1. Solid organ market revenue, by type (2017-2030)
- 21.5. Market Revenue, by Application (2017-2030)
- 21.6. Market Revenue, by End User (2017-2030)
Chapter 22. Australia Market
- 22.1. Overview
- 22.2. Market Revenue, by Technology (2017-2030)
- 22.2.1. Molecular assay market revenue, by type (2017-2030)
- 22.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 22.3. Market Revenue, by Offering (2017-2030)
- 22.4. Market Revenue, by Transplant Type (2017-2030)
- 22.4.1. Solid organ market revenue, by type (2017-2030)
- 22.5. Market Revenue, by Application (2017-2030)
- 22.6. Market Revenue, by End User (2017-2030)
Chapter 23. South Korea Market
- 23.1. Overview
- 23.2. Market Revenue, by Technology (2017-2030)
- 23.2.1. Molecular assay market revenue, by type (2017-2030)
- 23.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 23.3. Market Revenue, by Offering (2017-2030)
- 23.4. Market Revenue, by Transplant Type (2017-2030)
- 23.4.1. Solid organ market revenue, by type (2017-2030)
- 23.5. Market Revenue, by Application (2017-2030)
- 23.6. Market Revenue, by End User (2017-2030)
Chapter 24. Brazil Market
- 24.1. Overview
- 24.2. Market Revenue, by Technology (2017-2030)
- 24.2.1. Molecular assay market revenue, by type (2017-2030)
- 24.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 24.3. Market Revenue, by Offering (2017-2030)
- 24.4. Market Revenue, by Transplant Type (2017-2030)
- 24.4.1. Solid organ market revenue, by type (2017-2030)
- 24.5. Market Revenue, by Application (2017-2030)
- 24.6. Market Revenue, by End User (2017-2030)
Chapter 25. Mexico Market
- 25.1. Overview
- 25.2. Market Revenue, by Technology (2017-2030)
- 25.2.1. Molecular assay market revenue, by type (2017-2030)
- 25.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 25.3. Market Revenue, by Offering (2017-2030)
- 25.4. Market Revenue, by Transplant Type (2017-2030)
- 25.4.1. Solid organ market revenue, by type (2017-2030)
- 25.5. Market Revenue, by Application (2017-2030)
- 25.6. Market Revenue, by End User (2017-2030)
Chapter 26. Saudi Arabia Market
- 26.1. Overview
- 26.2. Market Revenue, by Technology (2017-2030)
- 26.2.1. Molecular assay market revenue, by type (2017-2030)
- 26.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 26.3. Market Revenue, by Offering (2017-2030)
- 26.4. Market Revenue, by Transplant Type (2017-2030)
- 26.4.1. Solid organ market revenue, by type (2017-2030)
- 26.5. Market Revenue, by Application (2017-2030)
- 26.6. Market Revenue, by End User (2017-2030)
Chapter 27. South Africa Market
- 27.1. Overview
- 27.2. Market Revenue, by Technology (2017-2030)
- 27.2.1. Molecular assay market revenue, by type (2017-2030)
- 27.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 27.3. Market Revenue, by Offering (2017-2030)
- 27.4. Market Revenue, by Transplant Type (2017-2030)
- 27.4.1. Solid organ market revenue, by type (2017-2030)
- 27.5. Market Revenue, by Application (2017-2030)
- 27.6. Market Revenue, by End User (2017-2030)
Chapter 28. U.A.E. Market
- 28.1. Overview
- 28.2. Market Revenue, by Technology (2017-2030)
- 28.2.1. Molecular assay market revenue, by type (2017-2030)
- 28.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 28.3. Market Revenue, by Offering (2017-2030)
- 28.4. Market Revenue, by Transplant Type (2017-2030)
- 28.4.1. Solid organ market revenue, by type (2017-2030)
- 28.5. Market Revenue, by Application (2017-2030)
- 28.6. Market Revenue, by End User (2017-2030)
Chapter 29. Competitive Landscape
- 29.1. List of Market Players and their Offerings
- 29.2. Competitive Benchmarking of Key Players
- 29.3. Product Benchmarking of Key Players
- 29.4. Recent Strategic Developments
Chapter 30. Company Profiles
- 30.1. bioMerieux S.A.
- 30.1.1. Business overview
- 30.1.2. Product and service offerings
- 30.1.3. Key financial summary
- 30.2. Thermo Fisher Scientific Inc.
- 30.2.1. Business overview
- 30.2.2. Product and service offerings
- 30.2.3. Key financial summary
- 30.3. Bio-Rad Laboratories Inc.
- 30.3.1. Business overview
- 30.3.2. Product and service offerings
- 30.3.3. Key financial summary
- 30.4. Abbott Laboratories
- 30.4.1. Business overview
- 30.4.2. Product and service offerings
- 30.4.3. Key financial summary
- 30.5. Hologic Inc.
- 30.5.1. Business overview
- 30.5.2. Product and service offerings
- 30.5.3. Key financial summary
- 30.6. F. Hoffmann-La Roche Ltd.
- 30.6.1. Business overview
- 30.6.2. Product and service offerings
- 30.6.3. Key financial summary
- 30.7. Laboratory Corporation of America Holdings
- 30.7.1. Business overview
- 30.7.2. Product and service offerings
- 30.7.3. Key financial summary
- 30.8. BAG Diagnostics GmbH
- 30.8.1. Business overview
- 30.8.2. Product and service offerings
- 30.8.3. Key financial summary
- 30.9. Illumina Inc.
- 30.9.1. Business overview
- 30.9.2. Product and service offerings
- 30.9.3. Key financial summary
Chapter 31. Appendix
- 31.1. Abbreviations
- 31.2. Sources and References
- 31.3. Related Reports
